Books > Medicine > Clinical & internal medicine > Gynaecology & obstetrics
|
Buy Now
Adjuvant Chemotherapy of Breast Cancer - Papers Presented at the 2nd International Conference on Adjuvant Chemotherapy of Breast Cancer, Kantonsspital St. Gallen, Switzerland, March 1 - 3, 1984 (Paperback, Softcover reprint of the original 1st ed. 1984)
Loot Price: R2,862
Discovery Miles 28 620
|
|
Adjuvant Chemotherapy of Breast Cancer - Papers Presented at the 2nd International Conference on Adjuvant Chemotherapy of Breast Cancer, Kantonsspital St. Gallen, Switzerland, March 1 - 3, 1984 (Paperback, Softcover reprint of the original 1st ed. 1984)
Series: Recent Results in Cancer Research, 96
Expected to ship within 10 - 15 working days
|
H.-J. Senn Adjuvant Chemotherapy (ACT) of breast cancer has now
emerged as one of the controversial su):>jects in clinical and
also experimental oncology. Driven by growing frustration about
stagnating cure rates in breast cancer [1,4] and stimulated by
elegant demonstration of highly curative effects of adjuvant
systemic therapy in animal models [6, 11] and in several childhood
neoplasias [15], researchers introduced ACT to the primary
treatment of breast cancer with great hope some 15 years ago. After
a first wave of isolated "historic" trials with generally limited
but in one case remarkable success [5, 9], a second generation of
ACT studies was initiated by NSABP investigators and oncology
centers in Europe [2, 6, 13]. These trials were well conducted
statistically and diagnostically, and all in the early 1970s
included a surgical control arm. Early and intermediate beneficial
effects on relapse-free survival (RFS) after 2-3 years median
observation time then prompted a whole series of ACT studies in
breast cancer. These "third-gener ation" studies usually regarded
some positive influence of ACT as a given fact, dropping surgical
control regimens and comparing different ACT regimens, hopefully in
a prospective, randomized way 1984 Fig. 1. The mushrooming of
adjuvant studies in breast cancer XII Introduction [reviews in 3,
14]. The "mushrooming" of ACT studies in breast cancer during the
last 10 and especially 5 years is demonstrated in Fig. 1, and it
gets really cumbersome even for the insider to keep on top of the
multitude of sometimes conflicting data.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.